App Logo
menu

Menu

close
expand_more

AML Resources

expand_less
/
/
AML News

AML News

Here you will find articles that discuss the latest advances in AML. You will be kept up to date on the newest FDA drug approvals for AML drugs and treatment combinations. You will also learn about newly published research studies and any advances or findings that may contribute to your AML treatment. We will discuss topics such as newly discovered AML genetic mutations, exciting advances on new therapies like CAR-T therapy and NK cells, and improvements in alloegenic stem cell transplant. 

 

Articles posted here will also aim to help answer common questions like "how is AML treated?", "how is AML diagnosed?", and "what causes AML?". 

 

With new AML research being published almost every day, there is a lot to keep track of. The articles in this category will help you stay informed of new AML treatment options and AML research findings which will ultimately make you an empowered patient. Being empowered allows you to take important information to your healthcare team for discussion that will further enhance and personalize your care. 

Article Category Image
List-tile-article

A Review of the Role of Vitamin D in AML

While vitamin D deficiency is widespread among many countries including the United States, your vitamin D level may be even more important if you have AML. There are several studies that have shown vitamin D deficiency is more common among people with acute leukemias, and that lower vitamin D levels in blood cancers may be associated with poorer outcomes and responses to treatment. 
List-tile-article

New NCCN Guidelines Address Who Should Get a 3rd COVID-19 Vaccine

New guidelines have been released from the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee to help cancer patients understand if and when to get a 3rd COVID-19 vaccine. The committee recommends that all patients with an active blood cancer receive a third dose regardless of whether they are receiving cancer therapy.
List-tile-article

Study Shows that 91% of AML Patients Produced Antibodies to COVID-19 Vaccine

A new study by the Leukemia and Lymphoma Society found that 91% of AML patients produced antibodies from COVID-19 vaccination compared to 75% of all blood cancer patients. Because not all AML patients will produce antibodies as a result of vaccination, it is still important to continue to take extra precautions such as mask wearing, social distancing and proper hand hygiene.
List-tile-article

FDA Approves Booster COVID Shot for Immunocompromised Individuals

People with compromised immune systems who already received two doses of the Pfizer or Moderna vaccines can now get a third shot to boost their protection from COVID-19. This authorization includes patients undergoing treatment for acute myeloid leukemia and those who have received a stem cell transplant within the past two years.
List-tile-article

FDA Approval for Shingrix to Prevent Shingles in AML

Immunocompromised patients are at a 3 to 18-fold increased risk of shingles infection compared to those with a well functioning immune system. This recent FDA approval expands the number of people who can be protected against shingles by Shingrix.
List-tile-article

Antibody Responses to the Pfizer-BioNTech Vaccine for Allogeneic Transplant Recipients

Immunocompromised patients were initially excluded from COVID-19 vaccination studies. So, how do we know how effective these vaccines are for AML patients who have gone through stem cell transplant? New studies are now following transplant recipients to determine what level of protection COVID-19 vaccines offer this group of patients.
List-tile-article

Johnson & Johnson Recalls Aerosol Sunscreen Brands Due to Discovered Benzene

Benzene, a ingredient known to cause AML has been identified in five Johnson & Johnson suncreen products. The company has recalled these aerosol sunscreen products and is offering refunds. Share this article with your friends and family to spread the word!
List-tile-article

Join our HealthTree for AML Facebook Groups: Together We Are Stronger

Join our Acute Myeloid Leukemia (AML) Facebook Groups to connect with others on a similar journey as you. We have groups for adult AML, childhood AML and AML caregivers. Sharing our experiences is how we grow individually but also as a community. We need each other in order to accelerate a cure for AML for all. Join today to give and receive support!
List-tile-article

Fresh Hope for Those With Chronic Graft vs Host Disease (GvHD)

Graft vs host disease affects up to 50% of patients after allogeneic stem cell transplant and 10-15% of these patients suffer from severe symptoms. A new drug called Rezurock will be available at the end of August 2021 to provide relief to those struggling with severe graft vs host disease.
List-tile-article

Palliative Care During Induction Chemotherapy for AML Improves Coping and Quality of Life

Adding palliative care healthcare professionals to your team during induction chemotherapy for AML can increase your ability to cope, improve your quality of life and reduce feelings of depression and anxiety

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811